These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26916894)

  • 41. The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma.
    Omura G; Ando M; Ebihara Y; Saito Y; Kobayashi K; Fukuoka O; Akashi K; Yoshida M; Asakage T; Yamasoba T
    BMC Cancer; 2017 Dec; 17(1):898. PubMed ID: 29282038
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modifying effect of mouse double minute-2 promoter variants on risk of recurrence for patients with squamous cell carcinoma of oropharynx.
    Zhang Y; Sturgis EM; Li Y; Wei Q; Huang Z; Li G
    Sci Rep; 2017 Jan; 7():39765. PubMed ID: 28045062
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.
    Peltonen JK; Vähäkangas KH; Helppi HM; Bloigu R; Pääkkö P; Turpeenniemi-Hujanen T
    Head Neck Oncol; 2011 Apr; 3():20. PubMed ID: 21513535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
    J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
    Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
    JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.
    Horikawa Y; Nadaoka J; Saito M; Kumazawa T; Inoue T; Yuasa T; Tsuchiya N; Nishiyama H; Ogawa O; Habuchi T
    Oncol Rep; 2008 Jul; 20(1):49-55. PubMed ID: 18575717
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.
    Ohnstad HO; Castro R; Sun J; Heintz KM; Vassilev LT; Bjerkehagen B; Kresse SH; Meza-Zepeda LA; Myklebost O
    Cancer; 2013 Mar; 119(5):1013-22. PubMed ID: 23165797
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma.
    Cotignola J; Chou JF; Roy P; Mitra N; Busam K; Halpern AC; Orlow I
    J Invest Dermatol; 2012 May; 132(5):1471-8. PubMed ID: 22336942
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
    Talseth BA; Meldrum C; Suchy J; Kurzawski G; Lubinski J; Scott RJ
    Int J Cancer; 2007 Feb; 120(3):563-5. PubMed ID: 17096342
    [TBL] [Abstract][Full Text] [Related]  

  • 50. p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy.
    Giatromanolaki A; Koukourakis M; Zaramboukas T; Skordalaki A; Arapantoni P; Georgoulias V; Fountzilas G
    Anticancer Res; 1998; 18(6B):4685-92. PubMed ID: 9891541
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.
    van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM
    BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer.
    Cirauqui B; Margelí M; Quiroga V; Quer A; Karachaliou N; Chaib I; Ramírez JL; Muñoz A; Pollán C; Planas I; Drozdowsky A; Rosell R
    Tumour Biol; 2016 Oct; 37(10):13435-13443. PubMed ID: 27465548
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck.
    Chen K; Hu Z; Wang LE; Sturgis EM; El-Naggar AK; Zhang W; Wei Q
    Carcinogenesis; 2007 Sep; 28(9):2008-12. PubMed ID: 17693666
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
    Tinhofer I; Budach V; Saki M; Konschak R; Niehr F; Jöhrens K; Weichert W; Linge A; Lohaus F; Krause M; Neumann K; Endris V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baumann M;
    Eur J Cancer; 2016 Apr; 57():78-86. PubMed ID: 26896955
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TP53 mutations and survival in squamous-cell carcinoma of the head and neck.
    Poeta ML; Manola J; Goldwasser MA; Forastiere A; Benoit N; Califano JA; Ridge JA; Goodwin J; Kenady D; Saunders J; Westra W; Sidransky D; Koch WM
    N Engl J Med; 2007 Dec; 357(25):2552-61. PubMed ID: 18094376
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between genetic polymorphisms in DNA mismatch repair-related genes with risk and prognosis of head and neck squamous cell carcinoma.
    Nogueira GA; Lourenço GJ; Oliveira CB; Marson FA; Lopes-Aguiar L; Costa EF; Lima TR; Liutti VT; Leal F; Santos VC; Rinck-Junior JA; Lima CS
    Int J Cancer; 2015 Aug; 137(4):810-8. PubMed ID: 25598504
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy.
    Wang S; Chen L; Zhao Q; Rong H; Wang M; Gong W; Zhou J; Wu D; Zhang Z
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):1073-82. PubMed ID: 23423487
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck.
    Vlatković N; El-Fert A; Devling T; Ray-Sinha A; Gore DM; Rubbi CP; Dodson A; Jones AS; Helliwell TR; Jones TM; Boyd MT
    Cancer; 2011 Jul; 117(13):2939-50. PubMed ID: 21692053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.